Study of breast cancer incidence in patients of lymphangioleiomyomatosis.

Molecular evidence has linked the pathophysiology of lymphangioleiomyomatosis (LAM) to that of metastatic breast cancer. Following on this observation, we assessed the association between LAM and subsequent breast cancer. An epidemiological study was carried out using three LAM country cohorts, from...

Descripción completa

Detalles Bibliográficos
Autores: Nuñez, Olivier, Román, Antonio, Johnson, Simon R, Inoue, Yoshikazu, Hirose, Masaki, Casanova, Álvaro, de Garibay, Gorka Ruiz, Herranz, Carmen, Bueno-Moreno, Gema, Boni, Jacopo, Mateo, Francesca, Petit, Anna, Climent, Fina, Soler, Teresa, Vidal, August, Sánchez-Mut, José Vicente, Esteller, Manel, López, José Ignacio, García, Nadia, Gumà, Anna, Ortega, Raúl, Plà, María Jesús, Campos, Miriam, Ansótegui, Emilio, Molina-Molina, María, Valenzuela, Claudia, Ussetti, Piedad, Laporta, Rosalía, Ancochea, Julio, Xaubet, Antoni, Pujana, Miguel Angel, Pollan-Santamaria, Marina
Tipo de recurso: artículo
Fecha de publicación:2016
País:España
Institución:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/12457
Acceso en línea:http://hdl.handle.net/20.500.12105/12457
Access Level:acceso abierto
Palabra clave:Biomarkers, Tumor
Breast Neoplasms
Female
Humans
Incidence
Japan
Lymphangioleiomyomatosis
Neoplasm Metastasis
Sequence Analysis, DNA
Spain
United Kingdom
Descripción
Sumario:Molecular evidence has linked the pathophysiology of lymphangioleiomyomatosis (LAM) to that of metastatic breast cancer. Following on this observation, we assessed the association between LAM and subsequent breast cancer. An epidemiological study was carried out using three LAM country cohorts, from Japan, Spain, and the United Kingdom. The number of incident breast cancer cases observed in these cohorts was compared with the number expected on the basis of the country-specific incidence rates for the period 2000-2014. Immunohistochemical studies and exome sequence analysis were performed in two and one tumors, respectively. All cohorts revealed breast cancer standardized incidence ratios (SIRs) ≥ 2.25. The combined analysis of all cases or restricted to pre-menopausal age groups revealed significantly higher incidence of breast cancer: SIR = 2.81, 95 % confidence interval (CI) = 1.32-5.57, P = 0.009; and SIR = 4.88, 95 % CI = 2.29-9.99, P = 0.0007, respectively. Immunohistochemical analyses showed positivity for known markers of lung metastatic potential. This study suggests the existence of increased breast cancer risk among LAM patients. Prospective studies may be warranted to corroborate this result, which may be particularly relevant for pre-menopausal women with LAM.

Similares en LA Referencia